Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, specifically in the form of alpha-tocopheryl succinate, has been studied for its potential role in supporting or treating Alzheimer's Disease (AD) due to its antioxidant properties. The rationale is based on the hypothesis that oxidative stress contributes to neuronal damage in AD, and antioxidants like vitamin E might mitigate this damage. Several clinical trials, most notably the DATATOP and the Alzheimer's Disease Cooperative Study, have investigated vitamin E (usually as alpha-tocopherol, not specifically alpha-tocopheryl succinate) in patients with AD or mild cognitive impairment. Some studies have shown modest benefits, such as a slower progression of functional decline in moderate AD at high doses (e.g., 2000 IU/day). However, other trials have failed to demonstrate significant cognitive improvement, and concerns about increased all-cause mortality with high-dose vitamin E supplementation have emerged from meta-analyses. There is no compelling evidence that alpha-tocopheryl succinate (a specific esterified form) is superior to other forms of vitamin E or is uniquely effective in AD. Overall, vitamin E has a limited scientific basis for use in AD, with modest effects at best, and safety concerns at high doses. Current guidelines do not recommend vitamin E as a primary treatment for Alzheimer's Disease.

More about Vitamin E (alpha-tocopheryl succinate)
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by Vitamin E (alpha-tocopheryl succinate)

Products containing Vitamin E (alpha-tocopheryl succinate)